Mandate

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing

December 04, 2018 Banking and Finance

Aprea Therapeutics AB, with headquarters in Stockholm (Solna), is a biotechnology company focused on the discovery and development of new cancer drugs reactivating the tumour suppressor protein p53. 

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million series C financing round, led by the Redmile Group and with participation by the new investor Rock Springs Capital and the existing shareholders 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management, Karolinska Development AB.

Vinge’s team consisted of Kristina Ekberg, Peter Issa and Tove Lövgren Frisk. 

Related

Vinge has advised Sertion AB in connection with the acquisition of Svensk Anläggning och Driftteknik AB

Through the acquisition, Sertion takes a further step in its development as a leading international infrastructure and installation group within complex HVAC systems, technical infrastructure, and industrial piping. Svensk Anläggning och Driftteknik AB specializes in certified welding and installation of industrial piping.
February 10, 2026

Vinge advises Mirova in connection with the acquisition of the Boarp, Dållebo and Fågelås wind farms

Vinge has advised Mirova, a subsidiary of Natixis Investment Managers focusing on sustainable investments, in connection with the acquisition of the three Swedish onshore wind farms Boarp, Dållebo and Fågelås.
February 10, 2026

Vinge has advised Bridgepoint in its acquisition together with Polaris of a majority stake in PDSVISION, a global leader in digital engineering

Headquartered in Stockholm, PDSVISION operates across North America, Europe and Asia. The company delivers integrated software and services that support digital transformation in product development and manufacturing, helping customers improve productivity and accelerate the journey from concept to production. The company has built a subscription-led business with ~SEK 1.7 billion in revenues, characterised by longstanding customer relationships and strong organic growth.
February 10, 2026